Trial · NCT02712346
The Role of Endothelin-1 in Sickle Cell Disease
NCT02712346, Phase 1, Completed, Augusta University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Role of Endothelin-1 in Sickle Cell Disease. Trials, record NCT02712346. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02712346
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Role of Endothelin-1 in Sickle Cell Disease
- NCT number
- NCT02712346
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 26 participants, actual
- Lead sponsor
- Augusta University
- Conditions
- Sickle Cell Anemia
- Interventions
- Ambrisentan, Placebo
- First posted
- 2016-03-18
- Last updated
- 2020-04-02
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and Tolerability of ambrisentan in patients with sickle cell disease measured by physical exam, vital signs, blood and urine testing, ECG (specified visits), concomitant medication review, adverse events review | Day 1 (Baseline) through Day 113 | |
| Secondary | Efficacy of ambrisentan in improving kidney function in patients with sickle cell disease measured by blood | Day 1 (Baseline), Day 15, Day 29, Day 57, Day 85, and Day 113 | measured by blood |
| Secondary | Efficacy of ambrisentan in decreasing TRJ velocity | Day 1 (Baseline) and at the end of the 12 week treatment period | measured by echocardiogram |
| Secondary | Efficacy of ambrisentan in decreasing inflammation | Day 1 (Baseline) through Day 113 | measurement of inflammatory markers in blood |
| Secondary | Efficacy of ambrisentan in improving micro-circulation | Day 1 (Baseline) and at the end of the 12 week treatment period | measured by forearm and skin blood flow measurements |
| Secondary | Efficacy of ambrisentan in improving macro-circulation | Day 1 (Baseline), and at the end of the 12 week treatment period | measured by Transcranial Doppler (TCD) |
| Secondary | Efficacy of ambrisentan in improving nociception/pain | Day 1 (Baseline), and at the end of the 12 week treatment period | performance of quantitative sensory testing |
| Secondary | Efficacy of ambrisentan in improving kidney function in patients with sickle cell disease measured by urine testing for microalbuminuria/proteinuria | Day 1 (Baseline), Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 113 | measured by urine testing for microalbuminuria/proteinuria |
| Secondary | Efficacy of ambrisentan in improving nociception/pain | Day 1 (Baseline) through the 12 week treatment period | assessment of pain diaries/questionnaires |
| Secondary | Efficacy of ambrisentan in improving nociception/pain | Day 1 (Baseline) through the 12 week treatment period | assessment of adverse events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37254256 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01HL117684 | The Role of Endothelin-1 in Sickle Cell Disease | KUTLAR, ABDULLAH; MEILER, STEFFEN; POLLOCK, DAVID M | AUGUSTA UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2013 to 2017 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02712346
GET https://conductscience.org/api/trials/v1/NCT02712346/registered